What's in Institut de Recherches Cliniques de Montreal's pipeline?

Institut de Recherches Cliniques de Montreal has 4 drugs in our index: 4 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Institut de Recherches Cliniques de Montreal's portfolio?

Top competitors by shared drug class: Boryung Pharmaceutical Co., Ltd, Bristol-Myers Squibb, Gan & Lee Pharmaceuticals., Jiangsu HengRui Medicine Co., Ltd., Les Laboratoires des Médicaments Stériles.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/institut-de-recherches-cliniques-de-montreal.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Institut de Recherches Cliniques de Montreal — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Institut de Recherches Cliniques de Montreal pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Thiazide Candesartan	Thiazide Candesartan	marketed
Atenolol Thiazide	Atenolol Thiazide	marketed	Beta-blocker and thiazide diuretic combination	Beta-1 adrenergic receptor; sodium-chloride cotransporter (thiazide-sensitive)	Cardiovascular
Candesartan Thiazide	Candesartan Thiazide	marketed	Angiotensin II receptor blocker / Thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter	Cardiovascular
Detemir or Glargine	Detemir or Glargine	marketed	Long-acting basal insulin analog	Insulin receptor	Diabetes

Therapeutic area mix

Cardiovascular · 2
Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Boryung Pharmaceutical Co., Ltd · 1 shared drug class
Bristol-Myers Squibb · 1 shared drug class
Gan & Lee Pharmaceuticals. · 1 shared drug class
Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
Les Laboratoires des Médicaments Stériles · 1 shared drug class
Merete Bechmann Christensen · 1 shared drug class
Nanjing First Hospital, Nanjing Medical University · 1 shared drug class
Novo Nordisk A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Institut de Recherches Cliniques de Montreal:

Cite this brief

Drug Landscape (2026). Institut de Recherches Cliniques de Montreal — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-de-recherches-cliniques-de-montreal. Accessed 2026-05-18.